Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

References

• Dhama K, Khan S, Tiwari R, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33:e00028–20. doi:10.1128/CMR.00028-20
   PubMed Web of Science ®Google Scholar
• Dai R, Hu M, Tang H, Peng Z, Yan C, Emran TB. Efficacy and safety of convalescence plasma therapy in COVID-19 patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2022;2022:e7670817. doi:10.1155/2022/7670817
   PubMedGoogle Scholar
• Clark NM, Janaka SK, Hartman W, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS One. 2022;17(3):e0257930. doi:10.1371/journal.pone.0257930
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a Review. JAMA. 2020;324(8):782–793. doi:10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9. doi:10.1002/rmv.2141
   PubMed Web of Science ®Google Scholar
• Chen R, Lan Z, Ye J, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration. Front Immunol. 2021;12:589095.
   PubMed Web of Science ®Google Scholar
• Rahman M, Islam M, Shohag S, et al. Multifaceted role of natural sources for COVID-19 pandemic as marine drugs. Environ Sci Pollut Res. 2022;29:46527–46550. doi:10.1007/s11356-022-20328-5
   PubMed Web of Science ®Google Scholar
• Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.
   PubMed Web of Science ®Google Scholar
• Islam F, Dhawan M, Nafady MH, et al. Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the possible solutions. Ann Med Surg. 2022;78:103737. doi:10.1016/j.amsu.2022.103737
   PubMed Web of Science ®Google Scholar
• Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280–287. doi:10.1016/j.cca.2020.06.017
   PubMed Web of Science ®Google Scholar
• Nagant C, Ponthieux F, Smet J, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis. 2020;101:342–345. doi:10.1016/j.ijid.2020.10.003
   PubMed Web of Science ®Google Scholar
• Lippi G, Plebani M. Cytokine “storm”, cytokine “breeze”, or both in COVID-19? Clin Chem Lab Med. 2021;59(4):637–639. doi:10.1515/cclm-2020-1761
   Web of Science ®Google Scholar
• Boehm E, Kronig I, Neher RA, et al. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27:1109–1117.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–613. doi:10.1016/j.jinf.2020.03.037
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344. doi:10.1056/NEJMoa2028836
   PubMed Web of Science ®Google Scholar
• Bakhiet M, Taurin S. SARS-CoV-2: targeted managements and vaccine development. Cytokine Growth Factor Rev. 2021;58:16–29. doi:10.1016/j.cytogfr.2020.11.001
   PubMed Web of Science ®Google Scholar
• Klassen SA, Senefeld JW, Senese KA, et al. Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence. Front Med. 2021;8. doi:10.3389/fmed.2021.684151
   Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet Lond Engl. 2021;397(10278):1023–1034. doi:10.1016/S0140-6736(21)00306-8
   PubMed Web of Science ®Google Scholar
• Tharmarajah E, Buazon A, Patel V, et al. IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression. J Infect. 2021;82(5):178–185. doi:10.1016/j.jinf.2021.03.008
   PubMed Web of Science ®Google Scholar
• Cron RQ. COVID-19 cytokine storm: targeting the appropriate cytokine. Lancet Rheumatol. 2021;3(4):e236–e237. doi:10.1016/S2665-9913(21)00011-4
   PubMedGoogle Scholar
• Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–351. doi:10.1111/bjh.12629
   PubMed Web of Science ®Google Scholar
• Tabibi S, Tabibi T, Conic RRZ, Banisaeed N, Streiff MB. Therapeutic plasma exchange: a potential management strategy for critically ill COVID-19 patients. J Intensive Care Med. 2020;35(9):827–835. doi:10.1177/0885066620940259
   PubMed Web of Science ®Google Scholar
• Biçim S, Berber İ, Ali Erkurt M, et al. The prophylactic treatment of COVID-19 in a renal failure and Hodgkin lymphoma patient with convalescent plasma. IJR2H. 2022; 5 (2) : 1–5.
   Google Scholar
• Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfus Apher Sci. 2022;61(3):103355. doi:10.1016/j.transci.2022.103355
   PubMed Web of Science ®Google Scholar
• Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021;96(5):1262–1275. doi:10.1016/j.mayocp.2021.02.008
   PubMed Web of Science ®Google Scholar
• Nabil A, Uto K, Elshemy MM, et al. Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: an updated review until June 2020. EXCLI J. 2020;19:992–1016. doi:10.17179/excli2020-2554
   PubMed Web of Science ®Google Scholar
• Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–614. doi:10.1128/CMR.13.4.602
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703. doi:10.1038/nrmicro974
   PubMed Web of Science ®Google Scholar
• Rejeki MS, Sarnadi N, Wihastuti R, et al. Convalescent plasma therapy in patients with moderate-to-severe COVID-19: a study from Indonesia for clinical research in low- and middle-income countries. eClinicalMedicine. 2021;36:100931. doi:10.1016/j.eclinm.2021.100931
   PubMedGoogle Scholar
• Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet Lond Engl. 1979;314(8154):1216–1217. doi:10.1016/S0140-6736(79)92335-3
   Google Scholar
• Beigel JH, Tebas P, Elie-Turenne M-C, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, Phase 2 randomised study. Lancet Respir Med. 2017;5(6):500–511. doi:10.1016/S2213-2600(17)30174-1
   PubMed Web of Science ®Google Scholar
• Arnold Egloff SA, Junglen A, Restivo JSA, et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest. 2021;131(20):e151788. doi:10.1172/JCI151788
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888–1897. doi:10.1016/j.mayocp.2020.06.028
   PubMed Web of Science ®Google Scholar
• Cohn CS, Estcourt L, Grossman BJ, et al. COVID −19 convalescent plasma: interim recommendations from the AABB. Transfusion. 2021;61(4):1313–1323. doi:10.1111/trf.16328
   PubMed Web of Science ®Google Scholar
• Bloch EM, Tobian AAR, Shoham S, et al. How do I implement an outpatient program for the administration of convalescent plasma for COVID −19? Transfusion. 2022;62(5):933–941. doi:10.1111/trf.16871
   PubMed Web of Science ®Google Scholar
• Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus Trasfus Sangue. 2016;14:152–157.
   PubMed Web of Science ®Google Scholar
• McGuire LW, Redden WR. The use of convalescent human serum in influenza pneumonia—a preliminary report. Am J Public Health. 1918;8(10):741–744. doi:10.2105/AJPH.8.10.741
   Google Scholar
• Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi:10.1007/s10096-004-1271-9
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456. doi:10.1093/cid/ciq106
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:10.1056/NEJMoa1511812
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117(28):16587–16595. doi:10.1073/pnas.2009799117
   PubMed Web of Science ®Google Scholar
• Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734–743.e5. doi:10.1016/j.cell.2020.06.010
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis;2020. ciaa325. doi:10.1093/cid/ciaa325
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. doi:10.1038/s41586-020-03041-6
   PubMed Web of Science ®Google Scholar
• Cross RW, Prasad AN, Borisevich V, et al. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Rep. 2021;34(10):108837. doi:10.1016/j.celrep.2021.108837
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9–e13. doi:10.1016/j.chest.2020.03.039
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh-Cognasse H, Rosa M, et al. Inflammatory markers and auto-abs to type I IFNs in COVID-19 convalescent plasma; 2022;87:104414.
   Google Scholar
• Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:10.1172/JCI138003
   PubMed Web of Science ®Google Scholar
• Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci. 2020;59(3):102794. doi:10.1016/j.transci.2020.102794
   PubMed Web of Science ®Google Scholar
• Pool JG, Hershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203(4942):312. doi:10.1038/203312a0
   PubMedGoogle Scholar
• Franchini M. Convalescent plasma therapy for managing infectious diseases: a narrative review. Ann Blood. 2021;6:17. doi:10.21037/aob-2020-cp-03
   Google Scholar
• Psaltopoulou T, Sergentanis TN, Pappa V, et al. The emerging role of convalescent plasma in the treatment of COVID-19. HemaSphere. 2020;4(3):e409. doi:10.1097/HS9.0000000000000409
   PubMed Web of Science ®Google Scholar
• World Health Organization. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment During Outbreaks: Interim Guidance for National Health Authorities and Blood Transfusion Services. World Health Organization; 2014.
   Google Scholar
• Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609. doi:10.7326/0003-4819-145-8-200610170-00139
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:10.1093/infdis/jiu396
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus. 2015;4(1):709. doi:10.1186/s40064-015-1490-9
   PubMedGoogle Scholar
• Park WH, Freeman RG Jr. The prophylactic use of measles convalescent serum. J Am Med Assoc. 1926;87(8):556–558. doi:10.1001/jama.1926.02680080022009
   Google Scholar
• Park WH. Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. J Am Med Assoc. 1932;99(13):1050–1053. doi:10.1001/jama.1932.02740650008003
   Google Scholar
• Rambar AC. Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child. 1946;71(1):1–13. doi:10.1001/archpedi.1946.02020240008001
   Google Scholar
• Contreras-Barbeta E, Millan A, Rello J. Convalescent plasma for SARS-CoV-2 infection: win or learn. Eur Respir J. 2022;59(2):2102076. doi:10.1183/13993003.02076-2021
   PubMed Web of Science ®Google Scholar
• Brosig AM, Ossner T, Pamler I, et al. Multistep screening and selection of COVID-19 convalescent plasma donors at the early stage of the SARS-CoV-2 pandemic: a retrospective analysis. Health Sci Rep. 2022;5(5):e815. doi:10.1002/hsr2.815
   PubMedGoogle Scholar
• Chen B, Xia R. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: knowns and unknowns. Vox Sang. 2020;115(6):507–514. doi:10.1111/vox.12968
   PubMed Web of Science ®Google Scholar
• Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676–678. doi:10.1111/j.1469-0691.2004.00956.x
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study. MedRxiv. 2020;2020:2020. doi:10.1109/EMBC44109.2020.9175277
   Google Scholar
• Cristelli MP, Langhi Junior DM, Viana LA, et al. Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis. Transplantation. 2022;106:e92–e94. doi:10.1097/TP.0000000000003962
   PubMed Web of Science ®Google Scholar
• Budhai A, Wu AA, Hall L, et al. How did we rapidly implement a convalescent plasma program? Transfusion. 2020;60:1348–1355. doi:10.1111/trf.15910
   PubMed Web of Science ®Google Scholar
• FDA. Investigational COVID-19 convalescent plasma. U.S. Food and drug administration; 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma. Accessed October 18, 2022.
   Google Scholar
• Bacal CJO, Maina JW, Nandurkar HH, et al. Blood apheresis technologies – a critical review on challenges towards efficient blood separation and treatment. Mater Adv. 2021;2:7210–7236. doi:10.1039/D1MA00859E
   Google Scholar
• Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115:488–494. doi:10.1111/vox.12926
   PubMed Web of Science ®Google Scholar
• Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing b cell depletion therapy and those with humoral immunodeficiency states: a scoping review. Pathog Immun. 2021;6:76–103. doi:10.20411/pai.v6i1.435
   PubMedGoogle Scholar
• Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001. doi:10.1038/s41591-021-01507-2
   PubMed Web of Science ®Google Scholar
• Honjo K, Russell RM, Li R, et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Rep Med. 2021;2(1):100164. doi:10.1016/j.xcrm.2020.100164
   PubMedGoogle Scholar
• Dunbar NM, Yazer MH. Biomedical Excellence for Safer Transfusion (BEST) collaborative and the STAT study investigators. Safety of the use of group A plasma in trauma: the STAT study. Transfusion. 2017;57(8):1879–1884. doi:10.1111/trf.14139
   PubMedGoogle Scholar
• Bilir Y, Bilir A, Ciyiltepe F, Bombacı E, Saraçoglu A, Saraçoğlu KT. Comparison of the effectiveness of early and late convalescent plasma treatment given in patients diagnosed with coronavirus disease in intensive care unit. Kocaeli Med J. 2022;11(1):43–51. doi:10.5505/ktd.2022.39260
   Google Scholar
• Wang P, Liu L, Nair MS, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9:2091–2093. doi:10.1080/22221751.2020.1823890
   PubMed Web of Science ®Google Scholar
• Del Fante C, Franchini M, Baldanti F, et al. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion. 2021;61:830–838.
   PubMed Web of Science ®Google Scholar
• Wu -B-B, Gu D-Z, Yu J-N, Yang J, Shen W-Q. Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis. Infect Genet Evol. 2020;84:104485. doi:10.1016/j.meegid.2020.104485
   PubMed Web of Science ®Google Scholar
• Franchini M, Glingani C, Del Fante C, et al. The protective effect of O blood type against SARS-CoV-2 infection. Vox Sang. 2021;116:249–250.
   PubMed Web of Science ®Google Scholar
• Liumbruno GM, Marano G, Grazzini G, Capuzzo E, Franchini M. Solvent/detergent-treated plasma: a tale of 30 years of experience. Expert Rev Hematol. 2015;8(3):9490–9496. doi:10.1586/17474086.2015.1016906
   Web of Science ®Google Scholar
• Focosi D, Franchini M, Pirofski L, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022;35(3):e00200–e00221. doi:10.1128/cmr.00200-21
   PubMed Web of Science ®Google Scholar
• Cacilhas P, Caberlon E, Angoleri L, Fassina K, Ribeiro RN, Pinto LC. Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control. Braz J Med Biol Res. 2022;55:1.
   Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618. doi:10.1056/NEJMoa2033700
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629. doi:10.1056/NEJMoa2031304
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label Phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939. doi:10.1136/bmj.m3939
   PubMed Web of Science ®Google Scholar
• Baker JV, Lane HC. The fast and the furious: chasing a clinical niche for COVID-19 convalescent plasma. Ann Intern Med. 2022;175(9):1332–1334. doi:10.7326/M22-2329
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):115–408. doi:10.1056/NEJMoa2118542
   Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):695–703. doi:10.1016/j.chom.2016.01.007
   Web of Science ®Google Scholar
• Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022;386(18):44–46. doi:10.1056/NEJMoa2119657
   Web of Science ®Google Scholar
• Millat-Martinez P, Gharbharan A, Alemany A, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun. 2022;13(1):2583. doi:10.1038/s41467-022-29911-3
   PubMed Web of Science ®Google Scholar
• Focosi D, Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines. 2022;21(7):877–884. doi:10.1080/14760584.2021.1932475
   PubMed Web of Science ®Google Scholar
• Hueso T, Godron A-S, Lanoy E, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia. 2022;36(4):1025–1034. doi:10.1038/s41375-022-01511-6
   PubMed Web of Science ®Google Scholar
• Focosi D, Franchini M, Joyner MJ, Casadevall A, Sullivan DJ. Analysis of anti-omicron neutralizing antibody titers in different convalescent plasma sources. medRxiv. 2022;2021. doi:10.1101/2021.12.24.21268317
   Google Scholar
• Rijnders BJA, Huygens S, Mitjà O. Evidence-based dosing of convalescent plasma for COVID-19 in future trials. Clin Microbiol Infect. 2022;28:667–671. doi:10.1016/j.cmi.2022.01.026
   PubMed Web of Science ®Google Scholar
• Belcari G, Conti A, Mazzoni A, Lanza M, Mazzetti P, Focosi D. Clinical and virological response to convalescent plasma in a chronic lymphocytic leukemia patient with COVID-19 Pneumonia. Life. 2022;12:1098. doi:10.3390/life12071098
   PubMedGoogle Scholar
• Hegerova L, Gooley TA, Sweerus KA, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136:759–762. doi:10.1182/blood.2020006964
   PubMed Web of Science ®Google Scholar
• Liu STH, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26:1708–1713. doi:10.1038/s41591-020-1088-9
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290–2303. doi:10.1016/j.ajpath.2020.08.001
   PubMed Web of Science ®Google Scholar
• Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci. 2020;59(5):102875. doi:10.1016/j.transci.2020.102875
   PubMed Web of Science ®Google Scholar
• Belov A, Huang Y, Villa CH, et al. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol. 2022;97:770–779. doi:10.1002/ajh.26531
   PubMed Web of Science ®Google Scholar
• Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022;5(1):e2147375. doi:10.1001/jamanetworkopen.2021.47375
   PubMed Web of Science ®Google Scholar
• Pardiwalla B, Yadav A, Bhatia A, et al. Convalescent plasma to limit coronavirus associated complications: a proof of concept phase-2 clinical study at a designated COVID-19 hospital in Mumbai city. J Curr Med Res Opin. 2021;4(05):940–949. doi:10.15520/jcmro.v4i05.419
   Google Scholar
• Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–1561. doi:10.3201/eid2209.151164
   PubMed Web of Science ®Google Scholar
• Ko J-H, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–622. doi:10.3851/IMP3243
   PubMed Web of Science ®Google Scholar
• Zhang J-S, Chen J-T, Liu Y-X, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77(2):147–150. doi:10.1002/jmv.20431
   PubMed Web of Science ®Google Scholar
• Yeh K-M, Chiueh T-S, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922. doi:10.1093/jac/dki346
   PubMed Web of Science ®Google Scholar
• Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi:10.1172/JCI138745
   PubMed Web of Science ®Google Scholar
• Franchini M, Liumbruno GM, Piacentini G, Glingani C, Zaffanello M. The three pillars of COVID-19 convalescent plasma therapy. Life. 2021;11(4):354. doi:10.3390/life11040354
   PubMedGoogle Scholar
• Bloch EM, Goel R, Wendel S, et al. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. Vox Sang. 2021;116(1):18–35. doi:10.1111/vox.12970
   PubMed Web of Science ®Google Scholar
• Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med. 2021;16(8):2181–2191. doi:10.1007/s11739-021-02734-8
   PubMed Web of Science ®Google Scholar
• Rogers R, Shehadeh F, Mylona EK, et al. Convalescent plasma for patients with severe Coronavirus Disease 2019 (COVID-19): a matched cohort study. Clin Infect Dis. 2021;73(1):e208–e214. doi:10.1093/cid/ciaa1548
   PubMed Web of Science ®Google Scholar
• Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. doi:10.1111/bjh.17272
   PubMed Web of Science ®Google Scholar
• Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, et al. Convalescent plasma transfusion for the treatment of COVID-19—experience from Poland: a multicenter study. J Clin Med. 2020;10(1):E28. doi:10.3390/jcm10010028
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015–1027. doi:10.1056/NEJMoa2031893
   PubMed Web of Science ®Google Scholar
• Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021;385:1951–1960. doi:10.1056/NEJMoa2103784
   PubMed Web of Science ®Google Scholar
• Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27:2012–2024. doi:10.1038/s41591-021-01488-2
   PubMed Web of Science ®Google Scholar
• Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin. 2021;40:507–516.
   Web of Science ®Google Scholar
• Gupta A, Kute VB, Patel HV, et al. Feasibility of convalescent plasma therapy in kidney transplant recipients with severe COVID-19: a single-center prospective cohort study. Exp Clin Transplant. 2021;19:304–309.
   PubMed Web of Science ®Google Scholar
• Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2021;2(4):e138. doi:10.1016/S2666-5247(21)00030-6
   PubMedGoogle Scholar
• Bennett-Guerrero E, Romeiser JL, Talbot LR, et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized trial. Crit Care Med. 2021;49(7):1015–1025. doi:10.1097/CCM.0000000000005066
   PubMed Web of Science ®Google Scholar
• Bainbridge ED, Hsue PY, Esensten JH, et al. Characteristics of high-titer convalescent plasma and antibody dynamics after administration in patients with severe coronavirus disease 2019. Open Forum Infect Dis. 2021;8(8):ofab385. doi:10.1093/ofid/ofab385
   PubMed Web of Science ®Google Scholar
• Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J. 2022;59(2):2101471. doi:10.1183/13993003.01471-2021
   PubMed Web of Science ®Google Scholar
• Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(5):e2210880. doi:10.1001/jamanetworkopen.2022.10880
   PubMed Web of Science ®Google Scholar
• Ricke DO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.640093
   PubMed Web of Science ®Google Scholar
• Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. Int J Infect Dis. 2020;100:483–489.
   PubMed Web of Science ®Google Scholar
• Körper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021;131(20):e152264. doi:10.1172/JCI152264
   PubMed Web of Science ®Google Scholar
• Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197. doi:10.1016/S1473-3099(20)30483-7
   PubMed Web of Science ®Google Scholar
• Fung M, Nambiar A, Pandey S, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2021;23:e13477.
   PubMed Web of Science ®Google Scholar
• Bhurayanontachai R, Siripaitoon P, Kositpantawong N, Chusri S. The success of non-ABO-identical convalescent plasma transfusion in coronavirus disease 2019 (COVID-19) related acute respiratory distress syndrome (CARDS): a case-report: convalescent plasma for COVID-19. Clin Crit Care. 2022;30:e0002–2022. doi:10.54205/ccc.v30.254752
   Google Scholar
• Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561–1562. doi:10.1001/jama.2020.4940
   PubMed Web of Science ®Google Scholar
• Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020;34(3):145–150. doi:10.1016/j.tmrv.2020.04.001
   PubMed Web of Science ®Google Scholar
• Amri N, Tessier N, Bégin R, et al. Blood endothelial-cell extracellular vesicles as potential biomarkers for the selection of plasma in COVID-19 convalescent plasma therapy. Cells. 2022;11(19):3122. doi:10.3390/cells11193122
   PubMed Web of Science ®Google Scholar
• Bajpai M, Maheshwari A, Kumar S, et al. Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. An Acad Bras Ciênc. 2022;94. doi:10.1590/0001-3765202220210202
   PubMed Web of Science ®Google Scholar
• Bansal N, Raturi M, Bansal Y, Singh P. A novel scoring system for selecting the target patients of COVID-19 convalescent plasma therapy: a hypothesis. Transfus Clin Biol. 2022;29:89–91. doi:10.1016/j.tracli.2021.06.004
   PubMed Web of Science ®Google Scholar
• Bruiners N, Guerrini V, Ukey R, et al. Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms. medRxiv. 2022;2022. doi:10.1101/2022.02.03.22269612
   Google Scholar
• De Silvestro G, Marson P, La Raja M, et al. Outcome of SARS CoV-2 in patients treated with convalescent plasma: one-year of data from the Veneto region (Italy) Registry. Eur J Intern Med. 2022;97:42–49. doi:10.1016/j.ejim.2021.12.023
   PubMed Web of Science ®Google Scholar
• Gullo G, Cucinella G, Tumminello M, et al. Convalescent plasma use in pregnant patients with COVID19 related ARDS: a case report and literature review. Ital J Gynaecol Obstet. 2022;34:228. doi:10.36129/jog.2022.32
   Google Scholar
• Duan L, Xie Y, Wang Q, et al. Research on antibody changes and nucleic acid clearance in COVID-19 patients treated with convalescent plasma. Am J Transl Res. 2022;14:2655–2667.
   PubMed Web of Science ®Google Scholar
• Emma Diletta S, Virginia P, Francesco P, et al. Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection. J Clin Nephrol. 2022;6:9. doi:10.29328/journal.jcn.1001088
   Google Scholar
• Erol S, Tanaçan A, Apaydin H, et al. An evaluation of the results of convalescent plasma therapy applied to pregnant women diagnosed as COVID-19- positive in a pandemic center: a prospective cohort study. Turk J Med Sci. 2022;52:554–564. doi:10.55730/1300-0144.5346
   PubMed Web of Science ®Google Scholar
• Esteban I, Panighetti MT, Polack FP. Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma. Gates Open Res. 2022;6:110. doi:10.12688/gatesopenres.13725.1
   Google Scholar
• Freise NF, Gliga S, Fischer J, et al. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients - a matched pair analysis to the LEOSS cohort. Sci Rep. 2022;12(1):19035. doi:10.1038/s41598-022-23200-1
   PubMed Web of Science ®Google Scholar
• Fazeli A, Sharifi S, Behdad F, et al. Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19. Transfus Apher Sci. 2022;61:103321. doi:10.1016/j.transci.2021.103321
   PubMed Web of Science ®Google Scholar
• Fernández-Lázaro D, Ortega CD, Sánchez-Serrano N, et al. Convalescent plasma therapy, therapeutic formulations of repurposed drugs in 20th century epidemics against COVID-19: a systematic review. Pharmaceutics. 2022;14:1020. doi:10.3390/pharmaceutics14051020
   PubMed Web of Science ®Google Scholar
• Fernández-Sánchez V, Ventura-Enríquez Y, Cabello-Gutiérrez C, et al. Convalescent plasma to treat Covid-19: a randomized double blind 2 centers trial. Review. 2022. doi:10.21203/rs.3.rs-1277990/v1
   Google Scholar
• Fodor E, Müller V, Iványi Z, et al. Early transfusion of convalescent plasma improves the clinical outcome in severe SARS-CoV2 infection. Infect Dis Ther. 2022;11:293–304. doi:10.1007/s40121-021-00514-7
   PubMed Web of Science ®Google Scholar
• Franchini M, Glingani C, Donno GD, et al. Convalescent plasma for hospitalized COVID-19 patients: a single-center experience. Life. 2022;12:420. doi:10.3390/life12030420
   PubMedGoogle Scholar
• Franchini M, Focosi D, Percivalle E, et al. Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients. Viruses. 2022;14(7):1443. doi:10.3390/v14071443
   PubMed Web of Science ®Google Scholar
• Gharbharan A, GeurtsvanKessel CH, Jordans CCE, et al. Effects of treatment of Coronavirus Disease 2019 with convalescent plasma in 25 B-cell–depleted patients. Clin Infect Dis. 2022;74:1271–1274. doi:10.1093/cid/ciab647
   PubMed Web of Science ®Google Scholar
• Jain R, Mallya MV, Amoncar S, et al. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: experience from tertiary care hospital in western India. Transfus Clin Biol. 2022;29:60–64. doi:10.1016/j.tracli.2021.07.004
   PubMed Web of Science ®Google Scholar
• Kutsuna S, Saito S, Takamatsu Y, et al. Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. GHM Open. 2022;2(1):38–43.
   Google Scholar
• Kurnianda J, Hardianti MS, Triyono T, et al. Efficacy and safety of convalescent plasma therapy in patients with moderate-to-severe COVID-19: a non-randomized comparative study with historical control in a referral hospital in Indonesia. J Infect Public Health. 2022;15:100–108. doi:10.1016/j.jiph.2021.10.028
   PubMed Web of Science ®Google Scholar
• Leon J, Merrill AE, Rogers K, et al. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors. Transfus Apher Sci. 2022;61:103326. doi:10.1016/j.transci.2021.103326
   PubMed Web of Science ®Google Scholar
• Magyari F, Pinczés LI, Páyer E, et al. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. Ann Hematol. 2022;101(10):2337–2345. doi:10.1007/s00277-022-04924-6
   PubMed Web of Science ®Google Scholar
• Marconato M, Abela IA, Hauser A, et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. J Clin Invest. 2022;132(12). doi:10.1172/JCI158190
   PubMed Web of Science ®Google Scholar
• Mastroianni A, Greco S, Chidichimo L, et al. Challenges associated with convalescent plasma infusion therapy during pregnancy, a case report. Womens Health Bull. 2022;9:118–121.
   Google Scholar
• Mesina F, Julian J, Relos J, et al. Use of convalescent plasma therapy with Best Available Treatment (BAT) among hospitalized COVID-19 patients: a multi-center study. medRxiv. 2022;2022:2022.
   Google Scholar
• Nyström K, Hjorth M, Fust R, et al. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. BMC Infect Dis. 2022;22(1):362. doi:10.1186/s12879-022-07323-4
   PubMed Web of Science ®Google Scholar
• Novacescu AN, Duma G, Buzzi B, et al. Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID‑19 patients: a single centre non‑randomized controlled trial. Exp Ther Med. 2022;23:1–8. doi:10.3892/etm.2021.10923
   PubMed Web of Science ®Google Scholar
• Novacescu AN, Duma G, Sandesc D, Sorescu T, Licker M. The successful recovery of a critically ill COVID-19 patient, following the combination of therapeutic plasma exchange and convalescent plasma transfusion: a case report. Medicina. 2022;58:1088. doi:10.3390/medicina58081088
   PubMedGoogle Scholar
• Noor ES, Semedi BP, Kusuma E. The effect of convalescent plasma administration on increasing blood IGG and IGM levels as an effort to prevent death due to Covid-19 in ICU Panglima Sebaya hospital, Paser Regency, East Kalimantan. J Adv Health Med Sci. 2022;8. doi:10.20474/jahms-8.1
   Google Scholar
• Ostrovskaya EA, Kostin AI, Bulanov A. Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review. Ann Crit Care. 2022;2:108–120.
   Google Scholar
• Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and safety of COVID-19 Convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med. 2022;182:115–126. doi:10.1001/jamainternmed.2021.6850
   PubMed Web of Science ®Google Scholar
• Pan C, Chen H, Xie J, et al. The efficiency of convalescent plasma therapy in the management of critically ill patients infected with COVID-19: a matched cohort study. Front Med. 2022;9:822821. doi:10.3389/fmed.2022.822821
   Web of Science ®Google Scholar
• Pratama A, Djaharuddin I. Effectiveness and efficacy of convalescent plasma therapy in Covid-19 patients. In: C62. Expanding Our Insight into Covid-19. American Thoracic Society; 2022:A4568–A4568.
   Google Scholar
• Qin J, Wang G, Han D. Benefits of plasma exchange on mortality in patients with COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022;122:332–336. doi:10.1016/j.ijid.2022.06.014
   PubMed Web of Science ®Google Scholar
• Soleimani Z, Soleimani A. ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. J Matern Fetal Neonatal Med. 2022;35:3040–3043. doi:10.1080/14767058.2020.1797669
   PubMed Web of Science ®Google Scholar
• Sanz C, Nomdedeu M, Pereira A, et al. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. Transfusion. 2022;62:974–981. doi:10.1111/trf.16863
   PubMed Web of Science ®Google Scholar
• Shibeeb S. Effectiveness of convalescent plasma therapy in COVID-19 patients with haematological malignancies (preprint); 2022.
   Google Scholar